NNNN

Anbio Biotechnology (NASDAQ)

Healthcare — Medical Instruments & Supplies

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care testing, and laboratory markets. Anbio Biotechnology was incorporated in 2021 and is based in Frankfurt am Main, Germany.

None

$12.35

$-1.36 (-9.96%)

Price History

SMA 20 SMA 40 EMA 12 EMA 26 Bollinger

52-Week Range

Fundamentals

Market Cap	$541.84M
P/E Ratio (TTM)	82.30
Forward P/E	-
EPS (TTM)	$0.15
Dividend Yield	-
Profit Margin	74.06%
Revenue Growth	73.90%
ROE	27.05%
Debt/Equity	-
Recommendation	None
Analyst Target	-
Analysts	-
Indexes	NASDAQ

Technical Indicators

RSI (14)	29.8
Beta	-
SMA 20	-
SMA 40	-
52-Week High	$55.65
52-Week Low	$10.50
50-Day Avg	$24.24
200-Day Avg	$26.89
Avg Volume	33.4K
Volume	33.6K

Performance Analysis

BULLISH

NNNN shows predominantly bullish signals based on its fundamentals and technicals.

+ Trading near its 52-week low ($10.50), which could present a value opportunity.

+ RSI at 29.8 signals oversold conditions — a bounce may be ahead.

- Price is below both the 50-day and 200-day moving averages — in a downtrend.

- P/E of 82.3 is elevated — the market expects high growth or it may be overvalued.

+ Strong revenue growth of 73.9% year-over-year.

+ Healthy profit margin of 74.1%.

~ Wall Street consensus is "none".

Recent News

Loading news...

Last updated: Jul 02, 2026 13:23 UTC

Back to Screener Export Report